Gravely Annabel K, Claasen Marco P A W, Ivanics Tommy, Winter Erin, Peralta Peregrina, Selzner Markus, Sapisochin Gonzalo
Multi-Organ Transplant Program, University Health Network, Toronto, Ontario, Canada.
Department of Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Clin Transplant. 2025 Feb;39(2):e70086. doi: 10.1111/ctr.70086.
Low post-operative day (POD) 1 Factor V has been retrospectively associated with graft loss after liver transplantation when stratified by a cutoff of 0.36 U/mL. We aimed to validate this prospectively.
Patients transplanted at Toronto General Hospital were recruited (May 2018-March 2021). Factor V measurements were obtained on POD1-3, 5, and 7. Graft and patient survival at 3, 6, and 12 months were primary and secondary outcomes, respectively. We identified an optimal cutoff through receiver operating characteristic (ROC) analysis and the Youden index. Kaplan-Meier method and Log-rank tests were used to assess/compare survival.
One hundred and twenty-nine patients were included. One hundred and eight had Factor V >0.36 and 21 had ≤0.36 U/mL. This cutoff was predictive of 6- and 12-month graft survival and 12-month patient survival. With an optimal cutoff of 0.46 U/mL on POD1, 87 patients had Factor V >0.46 and 42 had ≤0.46 U/mL. Three-, 6-, and 12-month graft survival rates were 100%, 98.8%, and 98.8%, for patients with Factor V >0.46 U/mL, and 92.9%, 87.7%, and 87.7% for Factor V ≤0.46 U/mL. Similarly, 3-, 6-, and 12-month patient survival rates were 98.8%, 96.4%, and 95.0% for patients with Factor V >0.46 U/mL, and 92.9%, 88.0%, and 82.9% for Factor V ≤0.46 U/mL. Stratification below the novel cutoff was associated with decreased graft survival at months 3 (p = 0.012), 6 (p = 0.006), and 12 (p = 0.006), and decreased patient survival at 12 months (p = 0.022).
Factor V serves as an early biomarker for graft loss, with an optimal predictive cutoff of 0.46 U/mL in this prospective population. Validation of this new cutoff is necessary.
术后第1天(POD1)低凝血因子V水平在以0.36 U/mL为临界值分层时,已被回顾性研究证实与肝移植后移植物丢失有关。我们旨在对此进行前瞻性验证。
招募在多伦多综合医院接受移植的患者(2018年5月至2021年3月)。在POD1 - 3、5和7天进行凝血因子V测量。3个月、6个月和12个月时的移植物和患者生存率分别为主要和次要结局。我们通过受试者工作特征(ROC)分析和尤登指数确定最佳临界值。采用Kaplan - Meier法和对数秩检验来评估/比较生存率。
纳入129例患者。108例患者凝血因子V>0.36,21例患者≤0.36 U/mL。该临界值可预测6个月和12个月时的移植物生存率以及12个月时的患者生存率。POD1时最佳临界值为0.46 U/mL,87例患者凝血因子V>0.46,42例患者≤0.46 U/mL。凝血因子V>0.46 U/mL的患者3个月、6个月和12个月时的移植物生存率分别为100%、98.8%和98.8%,凝血因子V≤0.46 U/mL的患者分别为92.9%、87.7%和87.7%。同样,凝血因子V>0.46 U/mL的患者3个月、6个月和12个月时的患者生存率分别为98.8%、96.4%和95.0%,凝血因子V≤0.46 U/mL的患者分别为92.9%、88.0%和82.9%。低于新临界值分层与3个月(p = 0.012)、6个月(p = 0.006)和12个月(p = 0.006)时移植物生存率降低以及12个月时患者生存率降低(p = 0.022)相关。
凝血因子V可作为移植物丢失的早期生物标志物,在该前瞻性队列中最佳预测临界值为0.46 U/mL。有必要对这一新临界值进行验证。